P102 - Topic: AS06-Prognosis/AS06b-Predictive factors of response to treatment: NOVEL PREDICTIVE INDICATORS IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC NEOPLASMS (HR-MDS) TREATED WITH 5-AZACYTIDINE: CUMULATIVE DATA FROM THE HELLENIC MDS STUDY GROUP

Autor: Kotsianidis, I., Hatzimichael, E., Pappa, V., Galanopoulos, A., Kourakli, A., Diamantopoulos, P., Papageorgiou, S., Liapis, K., Papadopoulos, V., Papoutselis, M., Bouchla, A., Georgoulis, V., Vassilakopoulos, T., Solomou, E., Dimou, M., Vassilopoulos, G., Vardi, A., Papaioannou, M., Pontikoglou, C., Anagnostopoulos, A., Panayiotidis, P., Kontopidou, F., Harchalakis, N., Adamopoulos, N., Ximeri, M., Zikos, P., Megalakaki, A., Repousis, P., Kotsopoulou, M., Dryllis, G., Tsoukanas, D., Kyrtsonis, M.-C., Poulakidas, E., Bouronikou, E., Delimpasis, S., Mparmparousi, D., Papadaki, H., Vyniou, N.A., Symeonidis, A.

Publikováno v: In Leukemia Research May 2023 128 Supplement

Myelodysplastic neoplasm with isolated thrombocytopenia and immune thrombocytopenic purpura in adults: insights from a comparison of two national registries.

Autor: Liapis K; Department of Hematology, Democritus University of Thrace Medical School, Alexandroupolis, Greece. kosliapis@hotmail.com., Papadopoulos V; Department of Hematology, Democritus University of Thrace Medical School, Alexandroupolis, Greece., Pontikoglou C; Department of Hematology, University General Hospital of Heraklion, Heraklion, Crete, Greece., Vrachiolias G; Department of Hematology, Democritus University of Thrace Medical School, Alexandroupolis, Greece., Stavroulaki E; Department of Hematology, Benizeleion Hospital, Heraklion, Crete, Greece., Kourakli A; Greece Department of Internal Medicine, University Hospital of Patras, Rio, Greece., Lazaris V; Greece Department of Internal Medicine, University Hospital of Patras, Rio, Greece., Galanopoulos AG; Department of Clinical Hematology, Georgios Gennimatas Hospital, Athens, Greece., Papoutselis M; Department of Hematology, Democritus University of Thrace Medical School, Alexandroupolis, Greece., Papageorgiou SG; Second Department of Internal Medicine, Attikon University General Hospital, Athens, Greece., Diamantopoulos PT; First Department of Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece., Pappa V; Second Department of Internal Medicine, Attikon University General Hospital, Athens, Greece., Viniou NA; First Department of Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece., Τsokanas D; Department of Clinical Hematology, Georgios Gennimatas Hospital, Athens, Greece., Vassilakopoulos TP; Department of Hematology, Laikon General Hospital, National and Kapodistrian University of Athens, Athens, Greece., Hatzimichael E; Department of Hematology, University Hospital of Ioannina, Ioannina, Greece., Bouronikou E; Department of Hematology, University Hospital of Larissa, Larissa, Greece., Ximeri M; Department of Hematology, University General Hospital of Heraklion, Heraklion, Crete, Greece., Megalakaki A; Department of Hematology, Metaxa Oncology Hospital, Piraeus, Greece., Zikos P; Department of Hematology, Aghios Andreas General Hospital, Patras, Greece., Panayiotidis P; First Propedeutic Department of Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece., Dimou M; First Propedeutic Department of Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece., Karakatsanis S; Department of Hematology, Sotiria General Hospital, Athens, Greece., Papaioannou M; Department of Hematology, AHEPA University Hospital, Thessaloniki, Greece., Papadakis S; Department of Hematology, Democritus University of Thrace Medical School, Alexandroupolis, Greece., Vardi A; Department of Hematology and Stem cell Transplantation, Georgios Papanicolaou General Hospital, Thessaloniki, Greece., Kontopidou F; Second Department of Internal Medicine, National and Kapodistrian University of Athens, Hippokratio General Hospital, Athens, Greece., Harchalakis N; Department of Hematology and Bone Marrow Transplantation Unit, Evangelismos Hospital, Athens, Greece., Adamopoulos I; Department of Hematology and Thalassemia, Kalamata General Hospital, Kalamata, Greece., Symeonidis A; Department of Hematology, Benizeleion Hospital, Heraklion, Crete, Greece., Papadaki HA; Department of Hematology, University General Hospital of Heraklion, Heraklion, Crete, Greece., Kotsianidis I; Department of Hematology, Democritus University of Thrace Medical School, Alexandroupolis, Greece.

Publikováno v: Leukemia [Leukemia] 2023 Mar; Vol. 37 (3), pp. 708-711. Date of Electronic Publication: 2023 Jan 16.

Serum ferritin and ECOG performance status predict the response and improve the prognostic value of IPSS or IPSS-R in patients with high-risk myelodysplastic syndromes and oligoblastic acute myeloid leukemia treated with 5-azacytidine: a retrospective analysis of the Hellenic national registry of myelodysplastic and hypoplastic syndromes

Autor: Papageorgiou, S.G. Kotsianidis, I. Bouchla, A. Symeonidis, A. Galanopoulos, A. Viniou, N.-A. Hatzimichael, E. Vassilakopoulos, T.P. Gogos, D. Megalakaki, A. Zikos, P. Diamantopoulos, P. Kourakli, A. Giannoulia, P. Papoutselis, M. Poulakidas, E. Arapaki, M. Vardi, A. Anagnostopoulos, A. Mparmparousi, D. Papaioannou, M. Bouronikou, E. Dimou, M. Papadaki, H. Panayiotidis, P. Pappa, V.

Background: 5-azacytidine (5-AZA) improves survival of patients with higher-risk myelodysplastic syndromes (MDSs) and oligoblastic acute myeloid leukemia (AML); however, predictive factors for response and outcome have not been consistently studied.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2127::2f1346cbba3a388fdd0c272409f84d91
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3104904

The outcome of patients with high-risk MDS achieving stable disease after treatment with 5-azacytidine: A retrospective analysis of the Hellenic (Greek) MDS Study Group

Autor: Papageorgiou, S.G. Kontos, C.K. Kotsianidis, I. Vasilatou, D. Symeonidis, A. Galanopoulos, A. Bouchla, A. Hatzimichael, E. Repousis, P. Zikos, P. Viniou, N.-A. Poulakidas, E. Vassilakopoulos, T.P. Diamantopoulos, P. Diamantopoulos, M.A. Mparmparousi, D. Bouronikou, E. Papadaki, H. Panayiotidis, P. Pappa, V.

The demethylating factor 5-azacytidine (5-AZA) improves survival in intermediate-2 and high-risk myelodysplastic syndrome (MDS) patients [according to the International Prognostic Score System (IPSS)] responding to treatment. However, the outcome of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2127::224499392c34225e5bdf35d20b7ae8bd
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3086564

The prognostic value of monosomal karyotype (MK) in higher-risk patients with myelodysplastic syndromes treated with 5-Azacitidine: A retrospective analysis of the Hellenic (Greek) Myelodysplastic syndromes Study Group

Autor: Papageorgiou, S.G. Vasilatou, D. Kontos, C.K. Kotsianidis, I. Symeonidis, A. Galanopoulos, A.G. Hatzimichael, E. Megalakaki, A. Poulakidas, E. Diamantopoulos, P. Vassilakopoulos, T.P. Zikos, P. Papadaki, H. Mparmparousi, D. Bouronikou, E. Panayiotidis, P. Viniou, N.-A. Pappa, V.

In this study, we investigated the incidence and prognostic impact of monosomal karyotype (MK) in 405 higher-risk Myelodysplastic Syndromes (MDS) patients treated with 5-AZA. The MK was present in 66 out of 405 (16.3%) patients, most of whom had comp

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2127::8c977081807354576443849bb9bd354f
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3107292